Abstract
Following the demonstration by Rees et al. that the skin disease psoriasis is quite often responsive to treatment with methotrexate (MTX) other investigators began to examine its use in a wide variety of benign and malignant cutaneous diseases [1-6] (Tab. 1). Most of these diseases have been shown to arise as a result of severe inflammation, cellular hyperproliferation, tissue hyperplasia, or a combination of these. Because psoriasis is the most common of this group of diseases, estimated to occur in 1-2% of western European populations [7], much of the discussion on the use of MTX in skin disease will be given to MTX and its use in psoriasis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Rees RB, Bennett JH, Bostick WL (1955) Aminopterin for psoriasis. Arch Dermat 72: 133–143
McDonald CJ, Bertino JR. (1969) Parenteral methotrexate in psoriasis. Arch Dermat 100: 655–668
McDonald CJ, Bertino JR. (1978) Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor leucovorin. Cancer Treatment Reports 62 (7): 1009–1014
Lever WF, Goldberg HS (1969) Treatment of pemphigus vulgaris with methotrexate. Arch Dermat 100: 70–78
Jorizzo JL, White WL, Wise CM (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis and Behcet’s disease. J Am Acad Dermat 24: 973–978
Knowles WR, Chernasky ME (1970) Pityriasis rubra pilaris, prolonged treatment with methotrexate. Arch Dermat 102: 603–612
Rea JN, Newhouse ML, Halil T (1976) Skin disease in Lambeth: a community study of prevalence and use of medical care. Br J Prey Soc Med 30: 107–114
Weinstein GD, McCullough JL (1991) Cell proliferation kinetics. In: HH Jr Roenigk, HI Maibach (eds): Psoriasis. 2nd ed. Marcel Dekker, New York, 327–342
Cooper KD (1990) Psoriasis: leucocytes and cytokines. Dermat Clin 8: 737–745
Braverman IM (1985) Microcirculation. In: HH Jr Roenigk, HI Maibach (eds): Psoriasis. Marcel Dekker, New York, 287–298
el-Sherif AI, Krupinski P, Majewski S, Jablonska S (1994) Leucocyte-extracellular matrix interactions in psoriasis. Int J Dermat 33: 371–373
Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M (1994) T-cells in psoriasis vulgaris belong to the TH 1 subset. Jlnvest Dermat 102: 145–159
Nickoloff BJ (1991) The cytokine network in psoriasis. Arch Dermat 127: 871–884
Krueger JG, Krane JF, Carter DM, Gottlieb AB (1990) Role of growth factors, cytokines and their receptors in the pathogenesis of psoriasis. Jlnvest Dermat 94 (Suppl): 135S–140S
Weinstein GD, Krueger JG (1993) An overview of psoriasis. In: GD Weinstein, AB Gottlieb (eds): Therapy of moderate to severe psoriasis. National Psoriasis Foundation, Portland, OR 1–23
Zachariae H, Sogaard H (1987) Methotrexate-induced liver cirrhosis: a follow up. Dermatologica 175: 178–182
Miller LC, Sisson BA, Tucker BA (1992) Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthr Rheum 35: 1143–1149
Boyd AS, Nelder KH (1994) Therapeutic options in dermatomyositis/polymyositis. Int J Dermat 33: 240–250
Schappell DL, Alper JC, McDonald CJ (1995) Treatment of advanced mycosis fungoides and Sezary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermat 131 (3): 307–313
Jennett CJ, Milling DM, Falk RJ (1994) Vasculitis affecting the skin. Arch Dermat 130: 899–906
Diaz-Perez JL, Winkelmann RK (1974) Cutaneous periarteritis nodosa. Arch Dermat 110: 407–414
Kammer GM, Soter NA, Schur PH (1980) Circulating immune complexes in patients with necrotizing vasculitis. Clin Immunol Immunopathol 15: 658–670
Braverman IM, Yen A (1975) Demonstration of immune complexes in spontaneous and histamine-induced lesions and in normal skin of patients with leukocytoclastic angiitis. J Invest Dermat 64: 105–112
Kallenberg CGM (1993) Autoantibodies in vasculitis: current perspectives. Clin Exp Rheum 11:355–360
Jordan JM, Allen NB, Pizo SV (1987) Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 82: 397–400
van der Woude TJ, Rasmussen N, Lobatto S (1985) Autoantibodies against neutrophils and monycytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1: 425–429
Cohen TJW, Huitema MG, Hene RJ (1990) Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336: 709–711
Jorizzo JL, White WL, Wise CM (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis and Behcet’s disease. J Am Acad Dermat 24: 973–978
Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthr Rheum 35: 1322–1329
Mobini N, Ahmed AR (1997) Bullous diseases: pathogenesis and treatment. In: McDonald CJ (ed): Immunomodulatory and cytotoxic agents in dermatology. Marcel Dekker, New York, 169–190
Bystryn JC (1985) Adjuvant therapy of pemphigus. Arch Dermat 120: 941–951
Griffiths WA, Pieris S (1982) Pityriasis rubra pilaris — an autoradiographic study. Br J Dermat 107 (6): 665–667
Veien NK, Brodthagen H (1977) Cutaneous sarcoidosis treated with methotrexate. Br J Dermat 97: 213–216
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Basel AG
About this chapter
Cite this chapter
McDonald, C. (2000). Use of methotrexate in the treatment of psoriasis and other dermatological disorders. In: Cronstein, B.N., Bertino, J.R. (eds) Methotrexate. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8452-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8452-5_7
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9573-6
Online ISBN: 978-3-0348-8452-5
eBook Packages: Springer Book Archive